Renaissance Technologies's CPRX Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 3.54 M shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $69.83 M, representing 0.09% of the portfolio. First purchased in 2013-Q3, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in CPRX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2022, adding 1.19 M shares. Largest reduction occurred in Q2 2018, reducing 1.24 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2013 | +138,500 | New Buy | 138,500 | $3.05 |
| Q4 2013 | -138,500 | Sold Out | 138,500 | $0.00 |
| Q3 2014 | +196,500 | New Buy | 196,500 | $3.32 |
| Q4 2014 | -196,500 | Sold Out | 196,500 | $0.00 |
| Q1 2015 | +21,227 | New Buy | 21,227 | $4.33 |
| Q2 2015 | -21,227 | Sold Out | 21,227 | $0.00 |
| Q1 2016 | +175,800 | New Buy | 175,800 | $1.17 |
| Q2 2016 | -175,800 | Sold Out | 175,800 | $0.00 |
| Q3 2016 | +15,000 | New Buy | 15,000 | $1.07 |
| Q4 2016 | -15,000 | Sold Out | 15,000 | $0.00 |
| Q1 2017 | +382,400 | New Buy | 382,400 | $1.95 |
| Q2 2017 | +509,400 | Add 133.21% | 891,800 | $2.76 |
| Q3 2017 | -310,200 | Reduce 34.78% | 581,600 | $2.52 |
| Q4 2017 | +532,500 | Add 91.56% | 1.11 M | $3.91 |
| Q1 2018 | +275,400 | Add 24.72% | 1.39 M | $2.39 |
| Q2 2018 | -1.24 M | Reduce 89.46% | 146,466 | $3.12 |
| Q3 2018 | +6,256 | Add 4.27% | 152,722 | $3.78 |
| Q4 2018 | -152,722 | Sold Out | 152,722 | $0.00 |
| Q4 2019 | +175,700 | New Buy | 175,700 | $3.75 |
| Q1 2020 | +563,526 | Add 320.73% | 739,226 | $3.85 |
| Q2 2020 | -739,226 | Sold Out | 739,226 | $0.00 |
| Q3 2021 | +52,238 | New Buy | 52,238 | $5.30 |
| Q4 2021 | +370,648 | Add 709.54% | 422,886 | $6.77 |
| Q1 2022 | -69,774 | Reduce 16.50% | 353,112 | $8.29 |
| Q2 2022 | +678,500 | Add 192.15% | 1.03 M | $7.01 |
| Q3 2022 | +1.19 M | Add 115.83% | 2.23 M | $12.83 |
| Q4 2022 | -995,000 | Reduce 44.69% | 1.23 M | $0.02 |
| Q1 2023 | -141,412 | Reduce 11.48% | 1.09 M | $0.02 |
| Q2 2023 | +64,800 | Add 5.94% | 1.15 M | $0.01 |
| Q3 2023 | +134,200 | Add 11.62% | 1.29 M | $11.69 |
| Q4 2023 | +308,327 | Add 23.92% | 1.6 M | $16.81 |
| Q1 2024 | +291,000 | Add 18.22% | 1.89 M | $15.94 |
| Q2 2024 | +287,300 | Add 15.21% | 2.18 M | $15.49 |
| Q3 2024 | +350,289 | Add 16.10% | 2.53 M | $19.88 |
| Q4 2024 | +180,100 | Add 7.13% | 2.71 M | $20.87 |
| Q1 2025 | +250,200 | Add 9.25% | 2.96 M | $24.25 |
| Q2 2025 | +295,200 | Add 9.99% | 3.25 M | $21.70 |
| Q3 2025 | +293,314 | Add 9.02% | 3.54 M | $19.70 |
Renaissance Technologies's Catalyst Pharmaceuticals Investment FAQs
Renaissance Technologies first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q3 2013, acquiring 138,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Catalyst Pharmaceuticals, Inc. (CPRX) for 49 quarters since Q3 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q3 2022, adding 2,226,512 shares worth $28.57 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 3,544,830 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $69.83 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.09% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 3,544,830 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.